Zobrazeno 1 - 10
of 1 235
pro vyhledávání: '"Philip Morris"'
Autor:
Philip Morris, Darryl Douglas
Publikováno v:
INTER-NOISE and NOISE-CON Congress and Conference Proceedings. 265:6538-6545
Aircraft designs may include an engine that exhausts over the upper fuselage of the aircraft. This design has many benefits including reduced noise below the aircraft. However, the scrubbing of the high-speed turbulent jet flow over the fuselage has
Autor:
Michael, Woodward, Henry, Brodaty, Maree, McCabe, Colin L, Masters, Sharon L, Naismith, Philip, Morris, Christopher C, Rowe, Peter, Walker, Mark, Yates
Publikováno v:
Journal of Alzheimer's Disease. 89:803-809
Prior to the usual clinical symptoms of dementia, there can be subtle changes in cognitive function that differ from the normal age-related cognitive decline, which has been termed mild cognitive impairment (MCI). The increase in the numbers of indiv
Publikováno v:
Fìnansi Ukraïni. 2021:100-112
The recent studies of levying excise tax on cigarettes and the policy of the EU and its member states aimed at setting a minimum excise tax thereon have been analyzed in order to substantiate recommendations on the respective reform in Ukraine. The a
Publikováno v:
Bìznes Inform, Vol 8, Iss 523, Pp 117-127 (2021)
The article is aimed at analyzing the provisions of the Draft Law of Ukraine «On Amendments to the Tax Code of Ukraine and Certain Legislative Acts of Ukraine on Ensuring the Balance of Budget Revenues» No. 5600 (hereinafter – the Draft Law) and
Publikováno v:
Fìnansi Ukraïni. 2021:82-96
The article analyses the ways to improve tobacco excise taxation in Ukraine considering a respective EU Member States experience, consequences of national reforms held in previous years, as well as challenges and potential threats caused by the pande
Autor:
Philip Morris Am, Patrick Parkinson Am
Publikováno v:
Australasian Psychiatry. 29:409-411
Objective: To examine laws in three Australian jurisdictions that prohibit therapy to change or suppress a person’s sexual orientation or gender identity. Conclusions: The laws in Victoria and the ACT provide inadequate protection for clinically ap
Autor:
Rosie Bradley, Jeremy Braybrooke, Richard Gray, Robert Hills, Zulian Liu, Richard Peto, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn Taylor, Stewart Anderson, Richard Gelber, Luca Gianni, William Jacot, Heikki Joensuu, Alvaro Moreno-Aspitia, Martine Piccart, Michael Press, Edward Romond, Dennis Slamon, Vera Suman, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Fran Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Yaochen Wang, John Crown, Evandro de Azambuja, Suzette Delaloge, Helena Fung, Charles Geyer, Marc Spielmann, Pinuccia Valagussa, Kathy Albain, Rodrigo Arriagada, John Bartlett, Elizabeth Bergsten-Nordström, Judith Bliss, Etienne Brain, Lisa Carey, Robert Coleman, Jack Cuzick, Nancy Davidson, Lucia Del Mastro, Angelo Di Leo, James Dignam, Mitch Dowsett, Bent Ejlertsen, Prue Francis, Michael Gnant, Matthew Goetz, Pam Goodwin, Pat Halpin-Murphy, Dan Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori Pierce, Philip Poortmans, Vinod Raina, Daniel Rea, Meredith Regan, John Robertson, Emiel Rutgers, Tanja Spanic, Joseph Sparano, Guenther Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Tim Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Kathleen I Pritchard, Sandra M Swain
Publikováno v:
The Lancet. Oncology
The lancet oncology
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) 2021, ' Trastuzumab for early-stage, HER2-positive breast cancer : a meta-analysis of 13 864 women in seven randomised trials ', The Lancet Oncology, vol. 22, no. 8, pp. 1139-1150 . https://doi.org/10.1016/S1470-2045(21)00288-6
The lancet oncology
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) 2021, ' Trastuzumab for early-stage, HER2-positive breast cancer : a meta-analysis of 13 864 women in seven randomised trials ', The Lancet Oncology, vol. 22, no. 8, pp. 1139-1150 . https://doi.org/10.1016/S1470-2045(21)00288-6
Background: Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxic
Autor:
Rosie Bradley, Jeremy Braybrooke, Richard Gray, Robert K Hills, Zulian Liu, Hongchao Pan, Richard Peto, David Dodwell, Paul McGale, Carolyn Taylor, Prudence A Francis, Michael Gnant, Francesco Perrone, Meredith M Regan, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Lucy Davies, Fran Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Raimund Jakesz, Christian Fesl, Olivia Pagani, Richard Gelber, Michelino De Laurentiis, Sabino De Placido, Ciro Gallo, Kathy Albain, Stewart Anderson, Rodrigo Arriagada, John Bartlett, Elizabeth Bergsten-Nordström, Judith Bliss, Etienne Brain, Lisa Carey, Robert Coleman, Jack Cuzick, Nancy Davidson, Lucia Del Mastro, Angelo Di Leo, James Dignam, Mitch Dowsett, Bent Ejlertsen, Matthew Goetz, Pam Goodwin, Pat Halpin-Murphy, Dan Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori Pierce, Philip Poortmans, Kathleen I Pritchard, Vinod Raina, Daniel Rea, John Robertson, Emiel Rutgers, Tanja Spanic, Joseph Sparano, Guenther Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Tim Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Sandra M Swain
Publikováno v:
Bradley, R, Braybrooke, J, Gray, R, Hills, R K, Liu, Z, Pan, H, Peto, R, Dodwell, D, McGale, P, Taylor, C, Francis, P A, Gnant, M, Perrone, F, Regan, M M, Berry, R, Boddington, C, Clarke, M, Davies, C, Davies, L, Duane, F, Evans, V, Gay, J, Gettins, L, Godwin, J, James, S, Liu, H, MacKinnon, E, Mannu, G, McHugh, T, Morris, P, Read, S, Straiton, E, Jakesz, R, Fesl, C, Pagani, O, Gelber, R, De Laurentiis, M, De Placido, S, Gallo, C, Albain, K, Anderson, S, Arriagada, R, Bartlett, J, Bergsten-Nordström, E, Bliss, J, Brain, E, Carey, L, Coleman, R, Cuzick, J, Ejlertsen, B & Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2022, ' Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression : a patient-level meta-analysis of 7030 women from four randomised trials ', The Lancet Oncology, vol. 23, no. 3, pp. 382-392 . https://doi.org/10.1016/S1470-2045(21)00758-0
Bradley, R, Braybrooke, J, Gray, R, Hills, R K, Liu, Z, Pan, H, Peto, R, Dodwell, D, Mcgale, P, Taylor, C, Francis, P A, Gnant, M, Perrone, F, Regan, M M, Berry, R, Boddington, C, Clarke, M, Davies, C, Davies, L, Duane, F, Evans, V, Gay, J, Gettins, L, Godwin, J, James, S, Liu, H, Mackinnon, E, Mannu, G, Mchugh, T, Morris, P, Read, S, Straiton, E, Jakesz, R, Fesl, C, Pagani, O, Gelber, R, De Laurentiis, M, De Placido, S, Gallo, C, Albain, K, Anderson, S, Arriagada, R, Bartlett, J, Bergsten-nordström, E, Bliss, J, Brain, E, Carey, L, Coleman, R, Cuzick, J, Davidson, N, Del Mastro, L, Di Leo, A, Dignam, J, Dowsett, M, Ejlertsen, B, Goetz, M, Goodwin, P, Halpin-murphy, P, Hayes, D, Hill, C, Jagsi, R, Janni, W, Loibl, S, Mamounas, E P, Martín, M, Mukai, H, Nekljudova, V, Norton, L, Ohashi, Y, Pierce, L, Poortmans, P, Pritchard, K I, Raina, V, Rea, D, Robertson, J, Rutgers, E, Spanic, T, Sparano, J, Steger, G, Tang, G, Toi, M, Tutt, A, Viale, G, Wang, X, Whelan, T, Wilcken, N, Wolmark, N, Cameron, D, Bergh, J & Swain, S M 2022, ' Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials ', The Lancet Oncology, vol. 23, no. 3, pp. 382-392 . https://doi.org/10.1016/S1470-2045(21)00758-0
Bradley, R, Braybrooke, J, Gray, R, Hills, R K, Liu, Z, Pan, H, Peto, R, Dodwell, D, Mcgale, P, Taylor, C, Francis, P A, Gnant, M, Perrone, F, Regan, M M, Berry, R, Boddington, C, Clarke, M, Davies, C, Davies, L, Duane, F, Evans, V, Gay, J, Gettins, L, Godwin, J, James, S, Liu, H, Mackinnon, E, Mannu, G, Mchugh, T, Morris, P, Read, S, Straiton, E, Jakesz, R, Fesl, C, Pagani, O, Gelber, R, De Laurentiis, M, De Placido, S, Gallo, C, Albain, K, Anderson, S, Arriagada, R, Bartlett, J, Bergsten-nordström, E, Bliss, J, Brain, E, Carey, L, Coleman, R, Cuzick, J, Davidson, N, Del Mastro, L, Di Leo, A, Dignam, J, Dowsett, M, Ejlertsen, B, Goetz, M, Goodwin, P, Halpin-murphy, P, Hayes, D, Hill, C, Jagsi, R, Janni, W, Loibl, S, Mamounas, E P, Martín, M, Mukai, H, Nekljudova, V, Norton, L, Ohashi, Y, Pierce, L, Poortmans, P, Pritchard, K I, Raina, V, Rea, D, Robertson, J, Rutgers, E, Spanic, T, Sparano, J, Steger, G, Tang, G, Toi, M, Tutt, A, Viale, G, Wang, X, Whelan, T, Wilcken, N, Wolmark, N, Cameron, D, Bergh, J & Swain, S M 2022, ' Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials ', The Lancet Oncology, vol. 23, no. 3, pp. 382-392 . https://doi.org/10.1016/S1470-2045(21)00758-0
Background: For women with early-stage oestrogen receptor (ER)-positive breast cancer, adjuvant tamoxifen reduces 15-year breast cancer mortality by a third. Aromatase inhibitors are more effective than tamoxifen in postmenopausal women but are ineff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::099cd29eddf49f551ce58241f52c0672
https://curis.ku.dk/portal/da/publications/aromatase-inhibitors-versus-tamoxifen-in-premenopausal-women-with-oestrogen-receptorpositive-earlystage-breast-cancer-treated-with-ovarian-suppression(f389c226-4a8e-4bac-aa3d-555d87bfdfab).html
https://curis.ku.dk/portal/da/publications/aromatase-inhibitors-versus-tamoxifen-in-premenopausal-women-with-oestrogen-receptorpositive-earlystage-breast-cancer-treated-with-ovarian-suppression(f389c226-4a8e-4bac-aa3d-555d87bfdfab).html
Autor:
Philip Morris International
Publikováno v:
Business Wire (English). 10/22/2024.